Trevi Therapeutics, Inc. (TRVI)
$18.08+0.67%Close
BUYBULL · day 5
Key stats
Short interest · FINRA settlement 2026-07-31
- Market cap
- $2.6B
- Avg volume
- 2.0M
- Beta
- 1.07
- P/E (TTM)
- -53.52
- Short % float
- 11.07%
- Days to cover
- 5.4
- SI change
- +3.9%
- 1W
- -2.16%
- 1M
- +3.08%
- 3M
- +27.95%
- YTD
- +52.06%
- vs SPY 1W
- -0.97%
- vs SPY 1M
- -0.24%
- vs SPY 3M
- +25.56%
- vs SPY YTD
- +40.31%
Sector peers
Same-sector names ranked by LOPJLB quality proximity · Healthcare
- AURABUYAura Biosciences, Inc.RECOVERYQ -3$7.90+1.28%
- AVBPSELLArriVent BioPharma, Inc. Common StockRECOVERYQ 21$28.26-2.95%
- AVLNBUYAvalyn Pharma Inc. Common StockQ 75$37.69-1.77%
- CLYMBUYClimb Bio, Inc.BULLQ 11$16.40-5.09%
- COAGBUYHemab Therapeutics Holdings, Inc. Common StockQ 70$46.67-5.07%
- DFTXSELLDefinium Therapeutics, Inc.RECOVERYQ 27$43.27-3.65%
- ELDNSELLEledon Pharmaceuticals, Inc.RECOVERYQ -11$3.41-1.16%
- ELVNBUYEnliven Therapeutics, Inc.BULLQ 15$61.15+2.22%
- EPRXBUYEupraxia Pharmaceuticals Inc.RECOVERYQ 46$7.28+8.17%
- GHRSBUYGH Research PLCBEARQ 19$28.10-0.81%
- GPCRBUYStructure Therapeutics Inc.RECOVERYQ 27$49.01-0.16%
- IMMXBUYImmix Biopharma, Inc.RECOVERYQ 29$13.61-0.37%
Industry peers
FMP comparable companies · ranked by market cap
- TERNTerns Pharmaceuticals, Inc.$4.8B$52.95
- PGENBUYPrecigen, Inc.$2.6BRECOVERYQ 9$7.17-0.42%
- ZYMEBUYZymeworks Inc.$2.1BRECOVERYQ 13$28.77+0.35%
- ZBIOSELLZenas BioPharma, Inc.$2.0BRECOVERYQ 20$31.65-1.98%
- NVAXBUYNovavax, Inc.$1.5BRECOVERYQ 9$8.86-0.89%
- ORICBUYORIC Pharmaceuticals, Inc.$1.4BBULLQ 4$13.46-5.21%
- TRMLTourmaline Bio, Inc.$1.2B$47.98
- WVESELLWave Life Sciences Ltd.$1.0BCRISISQ 9$5.12-3.21%
- ARDXSELLArdelyx, Inc.$924MCRISISQ 1$3.74-3.86%
Prediction markets
Kalshi · Polymarket · … linked
Loading markets…
FUNDAMENTALS
[SCORES & PROFILE]
- FUND
- 20
- VALUE
- 8
- GROWTH
- 47
- GARP
- 6
- TYPE
- Balanced
Composite of Value · Growth · GARP
ROIC-14.2%
REV YoY-
ROE-23.6%
EPS YoY-
ROA-15.5%
GROSS0
OP0
NET0
[VALUATION]
P/E TTM-53.52
P/E FWD-
SECTOR PE22.66
INDUSTRY PE17.07
P/B8.81
P/FCF-
EV/EBITDA-49.21
EV/EBIT-
PEG-
FCF YIELD-
RISK
INT COV-
D/E0.19
ALTMAN Z-
CURR RATIO37.28
ND/EBITDA-
BETA1.07
